Motley Fool A large influx of short-sellers shouldn't be a condemning factor for any company, but it could be a red flag from traders that something may not be as cut-and-dried as it appears. ... including the approval of Invokana, the first SGLT-2 inhibitor ...
Forbes (Like that blood-thinning drug , of course, overdose and other misuse is possible. By and large, though, most of the world is happy for the US to spend ... China's disputed claims to areas of the South and East China seas have garnered headlines of late ... and more »
PharmExec.com (blog) Being an observer rather than a participant in the drugs business makes it easier to sense those defining moments when something fundamental has changed, a limit is reached, and a new order emerges to reset the basic license to operate. As Pharm Exec ...
ESPN The components containing growth factors integral to healing are concentrated and then re-injected into the injury site. The idea is that overall ... And what if those things could be accomplished without the use of synthetic drugs ? This, many believe ...
FierceBiotech Five Prime comes to the table with only one featured drug candidate in Phase I development. GlaxoSmithKline ($GSK) is partnered on the experimental protein therapy, called FP-1039 or GSK 3052230, which targets cancer-promoting fibroblast growth factors ... and more »
Foreign Policy (blog) Writing for the Atlantic Council, Ross Wilson examines the factors behind growing tension among Syrians, Turks, and Kurds. On his blog Dart-Throwing Chimp, Jay Ulfelder offers some intriguing visualizations of data on state-sponsored mass killings. The ...
Trefis Owing to these factors , the global diabetes drug market has seen rapid growth in the last couple of years. According to GBI Research, a leading business intelligence provider, the type 2 diabetes drug market, which constitutes a significant chunk of ...
Surviving Mesothelioma The FDA recently announced its approval of afatinib, a drug which blocks epidermal growth factor receptor (EGFR) expression in cancer cells. M...
ABC Online Indeed, he says, the drug was specifically designed not to have anabolic effects. Unlike human growth hormone, AOD-9604 does not stimulate the production of IGF1 (Insulin-like Growth Factor 1), which is involved in growth and development, says Wittert.
